A combination of rivaroxaban and aspirin reduced overall and cardiovascular mortality compared with aspirin alone, with consistent reductions in cause-specific cardiovascular mortality in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD), according to an analysis of data from the COMPASS trial.